OVID 8-K 2026-11-10
Ovid Therapeutics Inc. (OVID) 8-K dated 2026-11-10 — accession 0001628280-26-072494.
Ovid Therapeutics Inc. (OVID) is a biotechnology company listed on US.
OVID: Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Finan…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported OVID revenue for 2026-06-30 was $733.0K. Net income was -$15.0M. OVID currently screens at market cap $23.5M.
Not investment advice. The OVID SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions r
Why it matters
- expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions r
- The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline,…